SA 9499

Drug Profile

SA 9499

Latest Information Update: 26 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santen Pharmaceutical
  • Class Antirheumatics
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 18 May 2004 Suspended - Preclinical for Inflammatory bowel disease in USA (unspecified route)
  • 18 May 2004 Suspended - Preclinical for Psoriasis in USA (unspecified route)
  • 18 May 2004 Suspended - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top